Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10327846" target="_blank" >RIV/00064165:_____/16:10327846 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10327846

Result on the web

<a href="http://dx.doi.org/10.1016/j.msard.2016.02.001" target="_blank" >http://dx.doi.org/10.1016/j.msard.2016.02.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2016.02.001" target="_blank" >10.1016/j.msard.2016.02.001</a>

Result language

angličtina

Original language name

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial

Original language description

Background: The SELECT study demonstrated superior effects of daclizumab high-yield process (DAC HYP) to placebo in key endpoints in patients with relapsing and remitting multiple sclerosis (RRMS). Objective: To assess the impact of DAC HYP and disease activity on health-related quality of life (HRQoL) using data from this study. Methods: HRQoL was assessed at baseline, 12, 24, and 52 weeks using the Multiple Sclerosis Impact Scale (MSIS-29), the 12-items Short Form Health Survey, and the EuroQoL-5 Dimensions. An analysis of covariance model was used to compare treatment difference in change from baseline. Mixed-effects models were used to assess the impact of disability progression, relapse, treatment, and interaction between treatment and these events on HRQoL outcome. Results: DAC HYP 150 mg resulted in significant positive impacts on HRQoL compared to placebo. It was also found to significantly reduce the adverse impact of relapse on the MSIS-29 physical scale (-12.45; p=0.0006). Relapse and disability progression were significantly associated with impaired HRQoL. Conclusion: DAC HYP 150 mg improved HRQoL in patients with RRMS compared to placebo. The treatment benefit can be partially attributed to reduction in disease activity and attenuation of the adverse impact of relapse on HRQoL.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Volume of the periodical

6

Issue of the periodical within the volume

March

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

66-72

UT code for WoS article

000375044800012

EID of the result in the Scopus database

2-s2.0-84962536674